• Je něco špatně v tomto záznamu ?

Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG)

A. Conconi, A. Janikova, B. Vannata, AF. Ramírez-Ibarguen, C. Lobetti-Bodoni, D. Belada, MC. Pirosa, M. Mian, AJM. Ferreri, G. Ryan, G. Pangalis, ME. Cabrera, S. Luminari, S. Montoto, R. Tsang, I. Aurer, C. Visco, GM. Casaluci, V. Prochazka, S....

. 2025 ; 43 (4) : e70111. [pub] -

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25015165

The characteristics at diagnosis and clinical course of primary extranodal follicular lymphoma (EFL) have not been extensively described. The International Extranodal Lymphoma Study Group (IELSG) conducted an international retrospective survey aimed to describe the clinical features at diagnosis and the outcomes of FL cases with a clinically dominant extranodal component. The dataset included 605 pathologically reviewed cases from 19 different countries, and their outcomes were compared to those of nodal follicular lymphomas. The two most common presentation sites for EFL were the skin (n = 334) and the gastrointestinal tract (n = 72), with 22 cases having primary duodenal localization. These subsets exhibited unique features at diagnosis and significantly different overall survival (OS) patterns. After a median follow-up of 5.5 years, primary cutaneous lymphomas showed a superior outcome [10-year OS: 89% (95% CI, 83%-93%)], while primary gastrointestinal lymphomas had an intermediate outcome [10-year OS: 79% (95% CI, 59%-90%)]. Among the gastrointestinal lymphomas, primary duodenal lymphomas tended toward the best outcome [10-year OS: 95% (95% CI, 69%-99%)]. Other primary extranodal sites had inferior outcomes [10-year OS: 59% (95% CI, 48%-68%)], similar to primary nodal lymphomas [10-year OS: 57% (95% CI, 49%-64%)]. These findings support the identification of specific primary FL localizations as distinct entities with particular clinical and biological characteristics.

1st Faculty of Medicine Charles University General Hospital Prague Prague Czech Republic

AOU Maggiore della Carità Novara Italy

Azienda sanitaria locale Ematologia Ospedale degli Infermi Biella Italy

CHIMOMO Department Università degli Studi di Modena e Reggio Emilia Modena Italy

Department of Haemato Oncology St Bartholomew's Hospital London UK

Department of Hematology and Oncology University Hospital Brno Brno Czech Republic

Department of Hematology Hospital Clinic Univeritari Barcelona Spain

Department of Medicine Section of Hematology University of Verona Verona Italy

Department of Radiation Oncology Pete MacCallum Cancer Institute Melbourne Australia

Division of Hematology and Medical School University Hospital Centre Zagreb Zagreb Croatia

Division of Hematology Mayo Clinic Rochester SW USA

Faculty of Biomedical Sciences Institute of Oncology Research Università della Svizzera italiana Bellinzona Switzerland

Haematology Department A Tortora Hospital Pagani Italy

Hematology AUSL IRCCS of Reggio Emilia Reggio Emilia Italy

Hematology Department Athens Medical Center Psychion Branch Athens Greece

Hematology Department Instituto Nacional de Cancerologia Mexico City Mexico

Innovation Research and Teaching Service Hospital of Bolzano Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität Bolzano Bozen Italy

Istituto Cantonale di Patologia Ente Ospedaliero Cantonale Locarno Switzerland

Lymphoma Unit IRCCS Ospedale San Raffaele Milan Italy

Northwestern Medicine Hematology and Medical Oncology Chicago IL USA

Oncology Institute of Southern Switzerland Ente Ospedaliero Cantonale Bellinzona Switzerland

Pathology Unit IRCCS Ospedale San Raffaele Milan Italy

SCDU Ematologia Dipartimento di Medicina Traslazionale Unversità del Piemonte Orientale Novara Italy

SIB Swiss Institute of Bioinformatics Lausanne Switzerland

Universidad de Chile Hospital del Salvador Santiago Chile

University Health Network Princess Margaret Hospital Toronto Canada

University Hospital Hradec Králové Hradec Králové Czech Republic

University Hospital Olomouc Olomouc Czech Republic

University Vita Salute San Raffaele Milan Italy

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015165
003      
CZ-PrNML
005      
20250731090805.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1002/hon.70111 $2 doi
035    __
$a (PubMed)40544479
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Conconi, Annarita $u Azienda sanitaria locale, Ematologia, Ospedale degli Infermi, Biella, Italy $1 https://orcid.org/0000000219664339
245    10
$a Primary Extranodal Follicular Lymphoma: A Retrospective Survey of the International Extranodal Lymphoma Study Group (IELSG) / $c A. Conconi, A. Janikova, B. Vannata, AF. Ramírez-Ibarguen, C. Lobetti-Bodoni, D. Belada, MC. Pirosa, M. Mian, AJM. Ferreri, G. Ryan, G. Pangalis, ME. Cabrera, S. Luminari, S. Montoto, R. Tsang, I. Aurer, C. Visco, GM. Casaluci, V. Prochazka, S. Hricko, A. Stathis, L. Mazzucchelli, M. Ponzoni, M. Federico, G. Gaidano, A. Lopez-Guillermo, B. Pro, D. Rossi, L. Cascione, G. Nowakowsky, M. Trneny, E. Zucca
520    9_
$a The characteristics at diagnosis and clinical course of primary extranodal follicular lymphoma (EFL) have not been extensively described. The International Extranodal Lymphoma Study Group (IELSG) conducted an international retrospective survey aimed to describe the clinical features at diagnosis and the outcomes of FL cases with a clinically dominant extranodal component. The dataset included 605 pathologically reviewed cases from 19 different countries, and their outcomes were compared to those of nodal follicular lymphomas. The two most common presentation sites for EFL were the skin (n = 334) and the gastrointestinal tract (n = 72), with 22 cases having primary duodenal localization. These subsets exhibited unique features at diagnosis and significantly different overall survival (OS) patterns. After a median follow-up of 5.5 years, primary cutaneous lymphomas showed a superior outcome [10-year OS: 89% (95% CI, 83%-93%)], while primary gastrointestinal lymphomas had an intermediate outcome [10-year OS: 79% (95% CI, 59%-90%)]. Among the gastrointestinal lymphomas, primary duodenal lymphomas tended toward the best outcome [10-year OS: 95% (95% CI, 69%-99%)]. Other primary extranodal sites had inferior outcomes [10-year OS: 59% (95% CI, 48%-68%)], similar to primary nodal lymphomas [10-year OS: 57% (95% CI, 49%-64%)]. These findings support the identification of specific primary FL localizations as distinct entities with particular clinical and biological characteristics.
650    _2
$a lidé $7 D006801
650    12
$a folikulární lymfom $x mortalita $x terapie $x diagnóza $x patologie $x epidemiologie $7 D008224
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a mladý dospělý $7 D055815
650    _2
$a prognóza $7 D011379
650    _2
$a následné studie $7 D005500
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Janikova, Andrea $u Department of Hematology and Oncology, University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/0000000226477769 $7 xx0103433
700    1_
$a Vannata, Barbara $u Haematology Department, A. Tortora Hospital, Pagani, Italy $1 https://orcid.org/0000000247864477
700    1_
$a Ramírez-Ibarguen, Ana Florencia $u Hematology Department, Instituto Nacional de Cancerologia, Mexico City, Mexico
700    1_
$a Lobetti-Bodoni, Chiara $u Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
700    1_
$a Belada, David $u University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Pirosa, Maria Cristina $u Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland $1 https://orcid.org/0000000152779835
700    1_
$a Mian, Michael $u Innovation, Research and Teaching Service, Hospital of Bolzano (SABES-ASDAA), Lehrkrankenhaus der Paracelsus Medizinischen Privatuniversität, Bolzano-Bozen, Italy
700    1_
$a Ferreri, Andrés J M $u Lymphoma Unit, IRCCS Ospedale San Raffaele, Milan, Italy $u University Vita-Salute San Raffaele, Milan, Italy
700    1_
$a Ryan, Gail $u Department of Radiation Oncology, Pete MacCallum Cancer Institute, Melbourne, Australia
700    1_
$a Pangalis, Gerassimos $u Hematology Department, Athens Medical Center-Psychion Branch, Athens, Greece
700    1_
$a Cabrera, Maria Elena $u Universidad de Chile, Hospital del Salvador, Santiago, Chile $1 https://orcid.org/0000000190593871
700    1_
$a Luminari, Stefano $u Hematology, AUSL IRCCS of Reggio Emilia, Reggio Emilia, Italy $u CHIMOMO Department, Università degli Studi di Modena e Reggio Emilia, Modena, Italy $1 https://orcid.org/0000000184462285
700    1_
$a Montoto, Silvia $u Department of Haemato-Oncology, St. Bartholomew's Hospital, London, UK
700    1_
$a Tsang, Richard $u University Health Network, Princess Margaret Hospital, Toronto, Canada
700    1_
$a Aurer, Igor $u Division of Hematology and Medical School, University Hospital Centre Zagreb, Zagreb, Croatia
700    1_
$a Visco, Carlo $u Department of Medicine, Section of Hematology, University of Verona, Verona, Italy
700    1_
$a Casaluci, Gloria Margiotta $u SCDU Ematologia, Dipartimento di Medicina Traslazionale, Unversità del Piemonte Orientale, Novara, Italy $u AOU Maggiore della Carità, Novara, Italy
700    1_
$a Prochazka, Vit $u University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Hricko, Samuel $u Department of Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Stathis, Anastasios $u Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
700    1_
$a Mazzucchelli, Luca $u Istituto Cantonale di Patologia, Ente Ospedaliero Cantonale, Locarno, Switzerland
700    1_
$a Ponzoni, Maurilio $u University Vita-Salute San Raffaele, Milan, Italy $u Pathology Unit, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Federico, Massimo $u Hematology, AUSL IRCCS of Reggio Emilia, Reggio Emilia, Italy
700    1_
$a Gaidano, Gianluca $u SCDU Ematologia, Dipartimento di Medicina Traslazionale, Unversità del Piemonte Orientale, Novara, Italy $u AOU Maggiore della Carità, Novara, Italy
700    1_
$a Lopez-Guillermo, Armando $u Department of Hematology, Hospital Clinic Univeritari, Barcelona, Spain
700    1_
$a Pro, Barbara $u Northwestern Medicine, Hematology and Medical Oncology, Chicago, IL, USA
700    1_
$a Rossi, Davide $u Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland $u Faculty of Biomedical Sciences, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland
700    1_
$a Cascione, Luciano $u Faculty of Biomedical Sciences, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland $u SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland
700    1_
$a Nowakowsky, Grzegorz $u Division of Hematology, Mayo Clinic, Rochester, SW, USA
700    1_
$a Trneny, Marek $u First Faculty of Medicine, Charles University General Hospital Prague, Prague, Czech Republic
700    1_
$a Zucca, Emanuele $u Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland $u Faculty of Biomedical Sciences, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland $1 https://orcid.org/0000000255226109
773    0_
$w MED00002019 $t Hematological oncology $x 1099-1069 $g Roč. 43, č. 4 (2025), s. e70111
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40544479 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731090800 $b ABA008
999    __
$a ok $b bmc $g 2366176 $s 1252290
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 43 $c 4 $d e70111 $e - $i 1099-1069 $m Hematological oncology $n Hematol Oncol $x MED00002019
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Možnosti archivace